Stock Events

Stock Events

GRI Bio 

$1.8300
54
+$0.06+3.39% 15:32 Today

Statistics

Day High
1.86
Day Low
1.7599
52W High
80.36
52W Low
1.7
Volume
100,654
Avg. Volume
-
Mkt Cap
3.24M
P/E Ratio
0.05
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19AugExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
Next
-35.84
-24.29
-12.74
-1.2
Expected EPS
-1.195
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-11.96MNet Income

Analyst Ratings

32.00Average Price Target
The highest estimate is 32.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GRI. It's not an investment recommendation.
Microsoft
7
MSFT
Tesla
7
TSLA
Apple
6
AAPL
JPMorgan Chase
6
JPM

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap201.93B
Amgen is a biotech firm that competes in developing innovative therapeutics in areas similar to GRI Bio, making it a direct competitor.
Gilead Sciences
GILD
Mkt Cap162.98B
Gilead Sciences operates in the biopharmaceutical sector focusing on antiviral drugs, directly competing with GRI Bio's research and development in similar therapeutic areas.
Biogen
BIIB
Mkt Cap31.91B
Biogen is known for its research in neurological diseases, potentially overlapping with GRI Bio's focus areas, hence a competitor.
Vertex Pharmaceuticals
VRTX
Mkt Cap134.02B
Vertex Pharmaceuticals focuses on creating drugs for complex diseases, which might intersect with GRI Bio's target diseases, making them competitors.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.59B
Regeneron Pharmaceuticals is involved in biopharmaceuticals, directly competing with GRI Bio in the development of innovative treatments.
Moderna
MRNA
Mkt Cap31.65B
Moderna is a leader in mRNA technology, which could be used in similar therapeutic areas as GRI Bio, positioning it as a competitor.
Alnylam Pharmaceuticals
ALNY
Mkt Cap41.76B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, a novel approach that could compete with GRI Bio's drug development strategies.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.4B
BioMarin Pharmaceutical focuses on rare genetic diseases, potentially competing with GRI Bio if they target similar conditions.
Novartis
NVS
Mkt Cap305.1B
Novartis is a large pharmaceutical company with a broad range of products that could compete across multiple areas with GRI Bio's portfolio.

Holdings

Regions

Sectors

About

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Show more...
CEO
Dr. W. Marc Hertz Ph.D.
Employees
4
Country
United States
ISIN
US3622AW5029

Listings

XNAS
US
GRI
BOATS
BOATS
GRI.BOATS

0 Comments

Share your thoughts

FAQ

What is GRI Bio stock price today?▼
The current price of GRI is $1.83 USD — it has increased by +3.39% in the past 24 hours. Watch GRI Bio stock price performance more closely on the chart.
What is GRI Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange GRI Bio stocks are traded under the ticker GRI.
Is GRI Bio stock price growing?▼
GRI stock has fallen by -3.74% compared to the previous week, the month change is a -18.18% fall, over the last year GRI Bio has showed a -96.13% decrease.
What is GRI Bio market cap?▼
Today GRI Bio has the market capitalization of 3.24M
When is the next GRI Bio earnings date?▼
GRI Bio is going to release the next earnings report on August 19, 2026.
What were GRI Bio earnings last quarter?▼
GRI earnings for the last quarter are -1.61 USD per share, whereas the estimation was -1.61 USD resulting in a -0.31% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is GRI Bio revenue for the last year?▼
GRI Bio revenue for the last year amounts to 0 USD.
What is GRI Bio net income for the last year?▼
GRI net income for the last year is -11.96M USD.
How many employees does GRI Bio have?▼
As of July 09, 2026, the company has 4 employees.
In which sector is GRI Bio located?▼
GRI Bio operates in the Health & Wellness sector.
When did GRI Bio complete a stock split?▼
The last stock split for GRI Bio was on January 26, 2026 with a ratio of 1:28.
Where is GRI Bio headquartered?▼
GRI Bio is headquartered in La Jolla, United States.